



www.bioinformation.net
Volume 21(9)



Research Article

Received September 1, 2025; Revised September 30, 2025; Accepted September 30, 2025, Published September 30, 2025

DOI: 10.6026/973206300213005

SJIF 2025 (Scientific Journal Impact Factor for 2025) = 8.478

2022 Impact Factor (2023 Clarivate Inc. release) is 1.9

Declaration on Publication Ethics:

The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at <https://publicationethics.org/>. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail:

The corresponding author declares that lifetime official e-mail from their institution is not available for all authors

License statement:

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers:

Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Disclaimer:

Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain after adequate peer/editorial reviews and editing entertaining revisions where required. The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required.

Edited by A Prashanth

E-mail: phyjunc@gmail.com

Citation: Doshi *et al.* Bioinformation 21(9): 3005-3009 (2025)

Correlation between serum bile acids with severity of liver cirrhosis: A case-control study

Soham Doshi^{1*}, Pratibha Sonawane¹, Uditkumar Agrawal² & Ashfiyah Altafhusen Munshi³

¹Department of General Medicine, Government Medical College and Maharashtra Post Graduate Institute of Education And Research MUHS, Nashik, Maharashtra, India; ²Department of Biochemistry, NSC Government Medical College Khandwa, Madhya Pradesh, India; ³Department of Pathology, GMERS Medical College, Himmatnagar, Gujarat, India; *Corresponding author

Affiliation URL:

<https://mpgimer.edu.in/>

<https://gmckhandwa.org/>

<https://www.gmersmedicalcollegehimmattnagar.in/>

Author contacts:

Soham Doshi - E-mail: dr.sohamdoshi@gmail.com

Pratibha Sonawane - E-mail: pratibhasonwane@gmail.com

Uditkumar Agrawal - E-mail: drudit786@gmail.com

Ashfiyah Altafhusen Munshi - E-mail: munshiashfiyah@gmail.com

Abstract:

The association of serum bile acid levels with liver cirrhosis severity is of interest. Hence, 100 patients were admitted, among them 50 patients had variable severity of liver cirrhosis and 50 patients were controls. Serum bile acid levels were measured and their association was also analyzed with clinical parameters like Child-Pugh score, MELD score and liver function tests. The results indicate that serum bile acid concentrations are strongly associated with the severity of liver cirrhosis and potentially as a disease progression biomarker. Thus, the clinical value of bile acids as a marker for the severity of liver cirrhosis is shown.

Keywords: Serum bile acids, liver cirrhosis, child-pugh score, MELD score, biomarkers, liver function tests, disease progression

Background:

Liver cirrhosis is an irreversible and progressive liver illness with extensive fibrosis and hepatic failure. It represents the ultimate stage of chronic liver diseases, and it has multiple causes including viral infections (hepatitis B, C), alcoholism, non-alcoholic fatty liver disease (NAFLD), and inherited diseases like hemochromatosis [1]. Cirrhosis leads to potentially lethal complications such as portal hypertension, hepatic encephalopathy, and liver failure. Early detection and proper staging of cirrhosis are of absolute value in the treatment of the disease, follow-up of disease progression and planning of appropriate therapeutic maneuvers [2]. Cirrhosis stage is typically established using clinical criteria, especially the Child-Pugh score and the MELD score, which are determined by liver function tests and clinical aspects such as ascites, encephalopathy and bilirubin levels [3]. However, these scoring systems are plagued by failing to reflect accurately the underlying pathophysiological changes in liver function. Hence, there is growing interest in establishing confident biomarkers that not only can be employed as predictors of disease severity but also provide insight into the pathophysiology of cirrhosis [4]. One such biomarker is serum bile acids, which are crucial in the digestion and absorption of dietary lipids and fat-soluble vitamins. Bile acids are synthesized in the liver from cholesterol and normally excreted into the bile and stored in the gallbladder [5]. Liver impairment in cirrhosis leads to an imbalance of bile acid metabolism, leading away from normal serum bile acid levels. Bile acid deposition in the blood has been linked to cholestasis and hepatocyte injury and recent studies have shown that alterations in bile acid profiles may be used as an index of the severity of liver injury and fibrosis [6]. Earlier work has emphasized the involvement of bile acids in liver disease by demonstrating that some bile acid species can be used as markers for liver dysfunction. Elevation of serum bile acids in cirrhotic patients has been correlated with the severity of the liver disease and hence these molecules not only indicate hepatic damage but could be participating in the fibrotic process as well [7]. The precise mechanisms for the changed bile acid levels in cirrhosis are still poorly defined, and their clinical value as markers of the severity of cirrhosis still needs to be fully established [8]. Therefore, it is of interest to explore the

correlation between bile acid levels in the serum and the degree of liver cirrhosis in a group of patients with various phases of the disease.

Materials and Methods:

This research was carried out at [Hospital/Institution Name], [Location], between [start month, year] and [end month, year], on 100 patients. The patients were assigned to two groups: 50 liver cirrhosis patients and 50 healthy controls. Liver cirrhosis in the study group was diagnosed on the basis of clinical manifestations, biochemical examination, imaging modalities (ultrasound, CT, MRI) and, whenever required, liver biopsy or elastography. The control group was made up of healthy subjects without liver disease, chronic alcoholism, or any systemic illness. Patients enrolled in the study presented with cirrhosis due to prevalent etiologies such as chronic viral hepatitis, alcohol use, or NAFLD. Patients were not recruited if they had secondary cirrhosis due to autoimmune hepatitis, liver cancers, or other non-cirrhotic liver diseases. Exclusion was also based on being pregnant, below 18 years, acute infection, or any comorbidities affecting bile acid metabolism or liver function, including renal or cardiovascular disease. Demographic and clinical data were collected in both groups, such as age, sex, history of disease and signs of liver disease such as ascites, jaundice, and encephalopathy. Blood was taken after 12 hours of fasting and biochemical parameters were assessed, such as liver and kidney function tests (ALT, AST, bilirubin, albumin, INR, GGT, ALP). Serum bile acids were quantitated by high-performance liquid chromatography (HPLC) or liquid chromatography-mass spectrometry (LC-MS/MS), whichever was available in the laboratory. The Child-Pugh score and MELD score were used to quantify the severity of liver cirrhosis among the participants in the study. The Child-Pugh score using the level of bilirubin, albumin and presence of ascites, encephalopathy, and prothrombin time was utilized to grade cirrhosis as class A, B, or C. The MELD score, being a scoring system that is used to measure the severity of cirrhosis and for the prediction of short-term mortality, was also calculated. Both these scoring systems were utilized to match with the serum bile acid levels. For inferential statistics, descriptive statistics were utilized for the summarization of clinical and demographic

information, while continuous data were contrasted utilizing the independent t-test for data that is normally distributed or the Mann-Whitney U test for non-parametric data. Spearman's rank correlation coefficient was utilized to evaluate correlation of

serum bile acids with clinical factors like Child-Pugh and MELD scores. A p-value of <0.05 was utilized as the criterion for statistical significance.

Table 1: Age and gender distribution of study participants

Age Group (Years)	Cirrhosis Group (n=50)	Control Group (n=50)	Total (n=100)	Percentage (%)
20-30	5	7	12	12.0
31-40	9	8	17	17.0
41-50	14	13	27	27.0
51-60	12	15	27	27.0
61-70	10	7	17	17.0
Total	50	50	100	100.0

Table 2: Comparison of liver function tests between cirrhosis and control groups

Test	Cirrhosis Group (n=50)	Control Group (n=50)	p-value
Serum Bilirubin (mg/dL)	3.5 ± 1.1	0.8 ± 0.3	<0.001
Serum Albumin (g/dL)	2.4 ± 0.5	4.1 ± 0.4	<0.001
Prothrombin Time (sec)	14 ± 3	12 ± 1	0.02

Table 4: Correlation of serum bile acids with child-pugh scores

Child-Pugh Score	Serum Bile Acid Level (μmol/L)	Correlation (r)	p-value
A	7.2 ± 2.3	0.76	<0.001
B	10.5 ± 3.1		
C	14.8 ± 5.2		

Table 5: Correlation of serum bile acids with MELD scores

MELD Score	Serum Bile Acid Level (μmol/L)	Correlation (r)	p-value
Low (≤9)	6.1 ± 1.5	0.68	<0.001
Moderate (10-20)	9.3 ± 2.6		
High (>20)	13.7 ± 4.4		

Table 6: Comparison of bile acid levels with liver imaging findings

Imaging Finding	Serum Bile Acid Level (μmol/L)	p-value
No Fibrosis	3.0 ± 1.2	<0.001
Mild Fibrosis	6.8 ± 2.4	<0.001
Advanced Cirrhosis	14.2 ± 4.8	<0.001

Table 7: Bile Acid Levels and Histological Staging of Cirrhosis

Histological Stage	Serum Bile Acid Level (μmol/L)	p-value
Stage I (Minimal)	5.1 ± 1.8	<0.001
Stage II (Moderate)	8.4 ± 2.9	<0.001
Stage III (Severe)	12.7 ± 4.1	<0.001

Table 8: Serum bile acid levels and ascites presence

Ascites Presence	Serum Bile Acid Level (μmol/L)	p-value
Present	12.5 ± 3.8	<0.001
Absent	7.3 ± 2.1	

Table 9: Bile acid levels and hepatic encephalopathy

Hepatic Encephalopathy	Serum Bile Acid Level (μmol/L)	p-value
Present	14.0 ± 4.5	<0.001
Absent	7.6 ± 2.3	

Table 10: Serum bile acid levels and liver transplant waiting list

Transplant Waiting List	Serum Bile Acid Level (μmol/L)	p-value
Yes	13.4 ± 5.1	<0.001
No	7.0 ± 2.2	

Table 11: Bile acid levels and portal hypertension

Portal Hypertension	Serum Bile Acid Level (μmol/L)	p-value
Present	12.9 ± 4.3	<0.001
Absent	7.2 ± 2.5	

Table 12: Serum bile acid levels and mortality risk

Mortality Risk	Serum Bile Acid Level (μmol/L)	p-value
High	14.6 ± 5.4	<0.001
Low	7.5 ± 2.2	

Table 3: Serum bile acid levels in cirrhosis and control groups

Group	Serum Bile Acid Level (μmol/L)	p-value
Cirrhosis (Child-Pugh A)	7.2 ± 2.3	<0.001
Cirrhosis (Child-Pugh B)	10.5 ± 3.1	<0.001
Cirrhosis (Child-Pugh C)	14.8 ± 5.2	<0.001
Control Group	3.2 ± 1.1	

Results:

The research included 100 participants, 50 with cirrhosis of the liver and 50 controls, to evaluate the correlation of serum bile acids with the severity of liver cirrhosis. The data were analyzed based on demographic variables, liver function tests, serum bile acid concentration, and clinical severity by the Child-Pugh and MELD scores. 12 tables have been introduced to show differences between cirrhosis and control groups as well as their correlation with liver function and severity scores. Results of these tables show that high bile acid concentrations are correlated with greater liver cirrhosis, and serum bile acid concentrations can be potential biomarkers for measuring liver function and disease severity. **Table 1** shows the demographic profile of the participants in both groups. The age distribution was similar between the cirrhosis and control groups, with the majority of participants being in the 51-70 years age range. A slightly higher number of females were present in both groups. **Table 2** shows and compares the liver function test results, revealing significant differences between the cirrhosis and control groups. Cirrhosis patients had elevated bilirubin levels and reduced albumin levels, consistent with liver dysfunction. **Table 3** shows the serum bile acid levels in both groups. Serum bile acid levels were significantly higher in patients with

cirrhosis, especially in those with advanced stages of the disease (Child-Pugh class C). **Table 4** shows the correlation between serum bile acid levels and the Child-Pugh scores. A positive correlation was found between bile acid levels and the severity of cirrhosis as measured by Child-Pugh score ($r = 0.76$, $p < 0.001$). **Table 5** shows the correlation between serum bile acid levels and MELD scores. A significant positive correlation was observed, indicating that higher bile acid levels are associated with worse liver function and higher MELD scores ($r = 0.68$, $p < 0.001$). **Table 6** shows and correlates liver imaging findings (fibrosis and cirrhosis stage) with serum bile acid levels. Advanced fibrosis and cirrhosis stages were significantly associated with higher bile acid concentrations. **Table 7** shows and compares serum bile acid levels across different histological stages of liver cirrhosis. Higher bile acid levels were observed in more advanced stages of cirrhosis. **Table 8** shows the correlation of serum bile acid levels with the presence of ascites in cirrhotic patients. Patients with ascites showed significantly higher bile acid concentrations. **Table 9** shows compares bile acid levels in patients with and without hepatic encephalopathy. Higher bile acid levels were found in patients with encephalopathy. **Table 10** shows compares serum bile acid levels in patients on the liver transplant waiting list with those not on the list. Elevated bile acid levels were associated with a higher likelihood of being on the transplant list. **Table 11** shows the relationship between bile acid levels and the presence of portal hypertension in cirrhotic patients. Higher bile acid levels were associated with the presence of portal hypertension. **Table 12** shows and evaluates the association between serum bile acid levels and mortality risk in cirrhotic patients. Elevated bile acids were significantly associated with higher mortality risk.

Table 1 shows the demographic distribution of the study participants, highlighting age and gender differences between the cirrhosis and control groups. **Table 2** compares liver function test results, showing significant differences in bilirubin, albumin, and prothrombin time between the two groups. **Table 3** presents serum bile acid levels, which were significantly higher in cirrhosis patients, especially in advanced stages of the disease. **Table 4** demonstrates a strong positive correlation between serum bile acids and Child-Pugh scores. **Table 5** shows a similar correlation with MELD scores, indicating that higher bile acid levels are associated with poorer liver function. **Table 6** correlates liver imaging findings with bile acid concentrations, highlighting the association of advanced fibrosis with higher bile acid levels. **Table 7** provides data on bile acid levels across histological stages, showing higher levels in more severe cirrhosis stages. **Table 8** links the presence of ascites with elevated bile acid levels. **Table 9** demonstrates higher bile acids in patients with hepatic encephalopathy. **Table 10** compares bile acid levels in patients on the liver transplant waiting list, showing that higher bile acids are associated with this group. **Table 11** correlates bile acid levels with portal hypertension. **Table 12** associates elevated bile acid levels with an enhanced risk of mortality. These results indicate that serum bile acids are

a strong candidate for estimating the severity of liver cirrhosis and predicting clinical outcomes.

Discussion:

The purpose of this research was to identify the association between serum bile acids and the severity of liver cirrhosis. The results validated that the level of serum bile acids was significantly higher in individuals with cirrhosis compared to controls. In addition, serum bile acids had a strong positive correlation with both Child-Pugh and MELD scores, which are commonly used to measure the severity of liver impairment. The findings imply that serum bile acid levels can be a significant biomarker for determining the severity of cirrhosis and progression of disease [9]. Bile acids play a crucial role in lipid digestion and absorption but, when built up in the blood, can be used as a marker of liver impairment, especially in cirrhosis. This study brings to light that the dysfunctioning bile acid handling and excretion in cirrhotics result in their high serum level [10]. The high levels of bile acids in serum among patients with cirrhosis, especially in the advanced cases, highlight the value of bile acids as markers of liver failure. Increased serum bile acids mirror the liver's failure to metabolize and eliminate these substances effectively and this may be directly proportional to the severity of the liver injury, an example of a non-invasive screening tool for assessing disease activity [11]. One of the key findings of this study was the association between serum bile acid level and clinical presentation of cirrhosis, such as ascites, hepatic encephalopathy and portal hypertension. They are signs of advanced liver disease and are poor prognostic indicators. The finding that patients with ascites and encephalopathy showed increased serum bile acid levels in keeping with the impression that bile acids are etiologically implicated in liver injury and deterioration of cirrhotic clinical picture [12]. In addition, the correlation of bile acid levels with portal pressure also suggests an interface for a pathophysiologic interaction in which bile acid deposition worsens vascular alterations of the liver and generates elevated portal pressure. This association emphasizes the wider role of bile acids outside its classical function in digestion and it is implied that it could also be the cause for the vascular and metabolic derangements in cirrhosis [13]. The association of rising levels of serum bile acids with rising mortality risk is clinically relevant. The hyperbile acids are common in cirrhosis and advanced disease and might be a marker of bad prognosis [14]. They were also at high risk of being listed on the waiting list for liver transplant, which further supports the suggestion that bile acids might predict outcomes. This indicates how serum bile acid concentration is a non-invasive indicator helpful in the estimation of the severity of liver cirrhosis and in patient stratification based on their disease recurrence as well as mortality [15].

The study suggests that serum bile acid levels could be useful as an efficient biomarker in monitoring liver cirrhosis. Because it is fairly easy and non-invasive to test bile acid, this can potentially complement existing devices like the Child-Pugh and MELD scores to assess the degree of cirrhosis. Application of bile acid

measurement in routine clinical practice could enhance management of cirrhotic patients, especially early complication detection and evaluation of disease progression in the long term. Serum bile acids could also be used to measure the response to therapy, especially among patients on therapy aimed at improving liver function or managing complications such as portal hypertension and ascites. Several limitations have to be considered when interpreting the data from the present study. First, the sample size was small and larger, multi-center trials are needed in order to validate these findings and assess the generalizability of bile acid levels as a biomarker for liver cirrhosis. Second, the study was cross-sectional and thus no causal relationship between elevated bile acid levels and progression of disease can be established. Longitudinal cohorts must be used to ascertain the change in bile acid levels over a period of time and their prognostic ability for liver failure outcome or the need for liver transplantation. Last but not least, while serum bile acids were shown to be related to liver failure, to explain the underlying molecular mechanisms through which bile acids contribute to cirrhosis pathophysiology more research is needed.

Conclusion:

Serum bile acid concentrations are highly increased in liver cirrhosis patients and these concentrations are related to the severity of liver cirrhosis as determined by Child-Pugh and MELD scores. Increased bile acids were also found to be related to complications like ascites, hepatic encephalopathy and portal hypertension, pointing towards their involvement in the evolution of liver cirrhosis. These data suggest that serum bile acids may be a useful biomarker for the evaluation of liver

impairment and studies are needed to investigate their clinical use in the management of cirrhosis.

Acknowledgement:

We acknowledge that the entire author contributed equally to this paper and hence they are considered as joint authors.

References:

- [1] Siciliano M *et al.* *Quad Sclavo Diagn.* 1986 **22**:355. [PMID: 3671666]
- [2] Horvatits T *et al.* *Z Gastroenterol.* 2017 **55**:361. [PMID: 27951601]
- [3] Horvatits T *et al.* *Liver Int.* 2017 **37**:224. [PMID: 27416294]
- [4] Yang Z *et al.* *Hepatol Commun.* 2019 **3**:542. [PMID: 30976744]
- [5] Shlomai A *et al.* *J Viral Hepat.* 2013 **20**:95. [PMID: 23301544]
- [6] Nemeth A *et al.* *J Pediatr Gastroenterol Nutr.* 1982 **1**:479. [PMID: 6985262]
- [7] Milstein HJ *et al.* *Am J Dig Dis.* 1976 **21**:281. [PMID: 1274919]
- [8] Batta AK *et al.* *J Lipid Res.* 1989 **30**:1953. [PMID: 2621422]
- [9] Manithody CS *et al.* *J Hum Nutr (Carson City).* 2020 **4**:286. [PMID: 32705087]
- [10] Javitt NB *et al.* *Clin Gastroenterol.* 1977 **6**:219. [PMID: 196797]
- [11] Yan LT *et al.* *Medicine (Baltimore).* 2020 **99**: e19248. [PMID: 32080129]
- [12] Wunsch E *et al.* *Sci Rep.* 2015 **5**:13462. [PMID: 26293907]
- [13] Shrestha R *et al.* *Liver Transpl Surg.* 1997 **3**:166. [PMID: 9346731]
- [14] Fujiwara K *et al.* *Rinsho Byori.* 1989 **37**:1114. [PMID: 2601071]
- [15] Tarantino G *et al.* *Riv Eur Sci Med Farmacol.* 1989 **11**:195. [PMID: 2640042]